The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Mylan Pharmaceuticals Inc. (a Viatris company) is conducting a recall at the retailer level of the above listed lots of Prasugrel Tablets, USP 5mg, packaged in 30 count bottles.
These lots are being recalled out of an abundance of caution due to out of specification dissolution results. These lots were distributed in the United States between July 19, 2024, and Feb 4, 2025.

The potential risk to patients arising from this issue is considered to be low. To date, no reports of adverse reactions associated with these lots have been received.

Prasugrel tablets are a P2Y12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows:

• Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI).
• Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI.

PRODUCT: Prasugrel Tablets, USP 5mg, bottle of 30 tablets

NDC Number: 0378-5185-93

LOT NUMBERS: 3211073, 3211074, 3211075

EXPIRATION DATE: April 2026 (For all lot numbers)